CBPE announces investment in Access Infinity
CBPE Capital has invested in Access Infinity, a provider of market access, pricing, and evidence strategy solutions for global pharmaceutical and biotech companies. The funding will support the company’s growth, including expanding its technology platform, enhancing services, and increasing its international footprint.
CBPE Capital (“CBPE”) is pleased to announce its investment in Access Infinity, a leading provider of market access, pricing, and evidence strategy solutions to the global pharmaceutical and biotech industries.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The company’s innovative software solutions (comprising Nuro, Access Hub and Evidence Hub) and expert consulting team help pharma clients navigate complex global market access challenges, optimise pricing strategies, and deliver value to patients across diverse healthcare systems.
CBPE’s investment will support Access Infinity as it accelerates its growth strategy, further develops its technology platform, and expands its international presence. The partnership will enable the company to continue investing in talent, innovation, and service offerings for its expanding customer base, which already includes 22 of the top 25 pharma companies.
CBPE has a strong track record of supporting ambitious, high-growth businesses in the healthcare and technology sectors. The investment in Access Infinity reflects CBPE’s confidence in the company’s leadership team and its commitment to supporting the next phase of growth.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The company’s innovative software solutions (comprising Nuro, Access Hub and Evidence Hub) and expert consulting team help pharma clients navigate complex global market access challenges, optimise pricing strategies, and deliver value to patients across diverse healthcare systems.
CBPE’s investment will support Access Infinity as it accelerates its growth strategy, further develops its technology platform, and expands its international presence. The partnership will enable the company to continue investing in talent, innovation, and service offerings for its expanding customer base, which already includes 22 of the top 25 pharma companies.
CBPE has a strong track record of supporting ambitious, high-growth businesses in the healthcare and technology sectors. The investment in Access Infinity reflects CBPE’s confidence in the company’s leadership team and its commitment to supporting the next phase of growth.
We are delighted to partner with CBPE for the next stage of our journey. Their experience and support will be invaluable as we continue to grow our business, invest in our people, and deliver exceptional value to our clients.Shrinivas Rao Mukku and Ahmed Edathodu, Founding Directors
Access Infinity
Shrinivas Rao Mukku and Ahmed Edathodu, Founding Directors
Access Infinity
We have been hugely impressed by Access Infinity’s expertise, innovation, and client-centric approach. We are excited to be working closely with the team to help realise their exciting plans for growth and continued leadership in the market access space.Naveen Passi, Partner
CBPE
Naveen Passi, Partner
CBPE
LikeDiscussion
Share
Discussion
You are commenting on CBPE announces investment in Access Infinity
You must be logged in to add a comment
There are no comments
Be the first to add to the discussion
Fund manager
CBPE Capital
London, United KingdomWe are a private equity firm that puts strong relationships with management at the heart of everything we do. We make only a small number of investments each year. And we make sure we have researched them carefully beforehand. The same goes for our relationships with management. We want to get to know the team thoroughly, and for them to know us, before we invest together. Our relationship based approach permeates every decision we make. We provide not just finance, but ongoing financial know-how and support from initial investment through to exit. Over 50% of our investments have made acquisitions after the initial investment. From identifying investment opportunities to working with management teams - we go about things in a straightforward no-nonsense way.
buyoutprivate equity
Related news
Blackstone Credit & Insurance Leads $1.3 Billion Financing to Support Combination of Paratek Pharmaceuticals and Radius Health
Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
Bridgepoint to Reinvest in Kyriba, Alongside New Minority Investor, General Atlantic
Partners Capital Investment Group Announces Minority Investment from General Atlantic
Blackstone Credit & Insurance Leads $7 Billion Investment in Sempra Infrastructure Partners’ Port Arthur LNG Phase 2
Charterhouse Capital Partners announces investment in Labelium
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
Stonepeak to Provide Equity Commitment to Longview Infrastructure
Stonepeak and Longview to partner on U.S. electric transmission infrastructure projects.